A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma.
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Pralatrexate (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms PROPEL
- Sponsors Acrotech Biopharma; Allos Therapeutics
- 14 Dec 2021 Results of efficacy and safety of pralatrexate by using data from four trials including this trial presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 01 Nov 2018 According to Servier media release, Servier Receives Health Canada Approval of FOLOTYN for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
- 06 Dec 2016 Case match control analysis results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.